Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

Area of Science:

• Immunology
• Endocrinology
• Clinical Trials

Background:

• Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta cells, leading to insulin deficiency.
• Teplizumab-mzwv is an immunotherapy approved to delay the onset of stage 3 T1D in at-risk individuals.
• Preserving endogenous insulin production is crucial for managing T1D and preventing long-term complications.

Purpose of the Study:

• To provide confirmatory evidence of teplizumab's efficacy in preserving endogenous insulin production.
• To analyze C-peptide levels as a measure of beta-cell function in patients treated with teplizumab.
• To assess the safety and tolerability of teplizumab across multiple clinical trials.

Main Methods:

• Integrated analysis of C-peptide data from 609 patients across five clinical trials in stage 3 T1D.
• Measurement of stimulated C-peptide levels from baseline at years 1 and 2.
• Analysis of exogenous insulin use and integrated safety data from 1,018 patients.

Main Results:

• Significant improvement in stimulated C-peptide levels at years 1 and 2 post-teplizumab treatment (P < 0.0001).
• Reduced exogenous insulin requirements observed at years 1 and 2 (P = 0.0001 and P < 0.0001, respectively).
• Common adverse events included lymphopenia, rash, and headache, which were generally self-limited.

Conclusions:

• Teplizumab consistently preserves beta-cell function, as indicated by C-peptide levels, across clinical trials.
• The drug demonstrates a favorable safety profile with self-limited adverse events.
• These findings support teplizumab's role in delaying T1D progression by maintaining insulin production.